Retained Earnings (Accumulated Deficit) in USD of Y-mAbs Therapeutics, Inc. from Q4 2017 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Y-mAbs Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) history and change rate from Q4 2017 to Q2 2025.
  • Y-mAbs Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending 30 Jun 2025 was -$496M, a 4.7% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2025 -$496M -$22.2M -4.7% 30 Jun 2025 10-Q 08 Aug 2025
Q1 2025 -$492M -$28.2M -6.08% 31 Mar 2025 10-Q 13 May 2025
Q4 2024 -$487M -$29.7M -6.49% 31 Dec 2024 10-Q 08 Aug 2025
Q3 2024 -$480M -$23.9M -5.23% 30 Sep 2024 10-Q 08 Nov 2024
Q2 2024 -$473M -$24.6M -5.49% 30 Jun 2024 10-Q 12 Aug 2024
Q1 2024 -$464M -$21.7M -4.9% 31 Mar 2024 10-Q 07 May 2024
Q4 2023 -$457M -$21.4M -4.91% 31 Dec 2023 10-K 04 Mar 2025
Q3 2023 -$456M -$19.3M -4.41% 30 Sep 2023 10-Q 13 Nov 2023
Q2 2023 -$449M -$39.1M -9.54% 30 Jun 2023 10-Q 10 Aug 2023
Q1 2023 -$442M -$73.9M -20% 31 Mar 2023 10-Q 08 May 2023
Q4 2022 -$436M -$95.6M -28.1% 31 Dec 2022 10-K 29 Feb 2024
Q3 2022 -$437M -$134M -44% 30 Sep 2022 10-Q 07 Nov 2022
Q2 2022 -$410M -$135M -49.1% 30 Jun 2022 10-Q 08 Aug 2022
Q1 2022 -$369M -$117M -46.4% 31 Mar 2022 10-Q 09 May 2022
Q4 2021 -$340M -$55.3M -19.4% 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 -$304M -$38.3M -14.4% 30 Sep 2021 10-Q 04 Nov 2021
Q2 2021 -$275M -$42.3M -18.2% 30 Jun 2021 10-Q 09 Aug 2021
Q1 2021 -$252M -$59.7M -31.1% 31 Mar 2021 10-Q 06 May 2021
Q4 2020 -$285M -$119M -71.9% 31 Dec 2020 10-K 01 Mar 2022
Q3 2020 -$265M -$123M -85.9% 30 Sep 2020 10-Q 05 Nov 2020
Q2 2020 -$232M -$114M -95.6% 30 Jun 2020 10-Q 06 Aug 2020
Q1 2020 -$192M -$91.3M -90.6% 31 Mar 2020 10-Q 07 May 2020
Q4 2019 -$166M -$81M -95.5% 31 Dec 2019 10-K 01 Mar 2021
Q3 2019 -$143M -$72M -102% 30 Sep 2019 10-Q 13 Nov 2019
Q2 2019 -$119M 30 Jun 2019 10-Q 14 Aug 2019
Q1 2019 -$101M 31 Mar 2019 10-Q 10 May 2019
Q4 2018 -$84.8M -$43.3M -104% 31 Dec 2018 10-K 12 Mar 2020
Q3 2018 -$70.8M 30 Sep 2018 10-Q 13 Nov 2018
Q4 2017 -$41.6M 31 Dec 2017 10-K 22 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.